Corporate ActionJun 30, 2026, 04:48 PM
Nuvectis Pharma Prices $100M Public Offering of Common Stock
AI Summary
Nuvectis Pharma, Inc. announced the pricing of its underwritten public offering of 5,000,000 shares of common stock at $20.00 per share, expecting gross proceeds of $100 million. The company anticipates net proceeds of approximately $93 million, which could increase to $107 million if the underwriters exercise their option to purchase an additional 750,000 shares. The funds are intended to advance the development programs for NXP100, NXP200, and NXP900, as well as for general corporate purposes.
Key Highlights
- Priced an underwritten public offering of 5,000,000 shares of common stock at $20.00 per share.
- Expected gross proceeds of $100 million from the offering.
- Expected net proceeds of approximately $93 million, or $107 million if the underwriters' option is fully exercised.
- Granted underwriters a 30-day option to purchase up to an additional 750,000 shares.
- Proceeds will advance development programs for NXP100, NXP200, and NXP900, and for general corporate purposes.
- Offering is expected to close on or about July 1, 2026.
Price Impact
More from NVCT